The Home Blood Pressure (BP) Trial

• Status: Not yet recruiting
• Trial end date: 2026-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The main study will be a two arm 10-month, cross-over randomized controlled trial of 200 participants treated with end-stage-kidney-disease treated with in-center hemodialysis in the Seattle and San Francisco area comparing a strategy of targeting home vs. pre-dialysis systolic blood pressure <140 mmHg to reduce rates of intradialytic hypotension. The target systolic blood pressure of <140 mmHg in both treatment groups will be achieved using an algorithm of dry weight adjustment and anti-hypertensive medication adjustment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of California, San Francisco
• Treatments: Antihypertensive Agents

Criteria

Inclusion Criteria:

• Aged 18 years or older

• Undergoing in-center, thrice weekly hemodialysis for treatment of end stage renal disease (ESRD)

• Greater than 3 months since initiation of dialysis

• No anticipated change to peritoneal dialysis or kidney transplant within 10 months

• Life expectancy greater than 10 months

• Hypertension (defined as mean pre-dialysis SBP > 140 mmHg over prior 2 weeks or taking BP medications)

• Able to obtain/measure a brachial blood pressure at dialysis and at home (e.g., no left ventricular assist device, blood pressure not been taken routinely in lower extremity at dialysis unit)

• No condition that the primary nephrologist or PIs feel precludes participation

Exclusion Criteria:

• Incarcerated or institutionalized (prohibits home blood pressure measurement)

• Participating in another intervention study that may affect blood pressure

• Pregnant or anticipated pregnancy or breastfeeding (as this will require increase to more than three times a week dialysis and/or preclude use of some classes of blood pressure medications)